US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
US5541087A
(en)
*
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6086875A
(en)
*
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6030613A
(en)
*
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
JPH11505421A
(ja)
*
|
1995-05-11 |
1999-05-21 |
ヒューマン ジノーム サイエンシーズ,インコーポレイテッド |
ヒトウリジンジホスフェートガラクトース−4−エピメラーゼ
|
EP0885012A4
(de)
*
|
1996-01-29 |
2001-09-05 |
Univ Georgetown |
Malaria impfstoff, der zusätzlich ein msa1 peptid enthält
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
CA2250141C
(en)
*
|
1996-03-25 |
2008-07-29 |
Pacific Northwest Cancer Foundation |
Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
|
TW517061B
(en)
*
|
1996-03-29 |
2003-01-11 |
Pharmacia & Amp Upjohn Ab |
Modified/chimeric superantigens and their use
|
WO1997040033A1
(en)
*
|
1996-04-19 |
1997-10-30 |
Lexigen Pharmaceuticals Corp. |
Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
US20050003431A1
(en)
*
|
1996-08-16 |
2005-01-06 |
Wucherpfennig Kai W. |
Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
|
MX340738B
(es)
*
|
1996-09-13 |
2016-07-22 |
Shire Human Genetic Therapies |
Terapia para deficiencia de a-galactosidasa a.
|
WO1998024886A1
(en)
*
|
1996-12-04 |
1998-06-11 |
Brigham And Women's Hospital, Inc. |
Mast cell protease that cleaves fibrinogen
|
ATE397061T1
(de)
*
|
1997-01-08 |
2008-06-15 |
Invitrogen Corp |
Verfahren zur herstellung von proteinen
|
WO1998033812A1
(en)
*
|
1997-02-05 |
1998-08-06 |
Brigham And Women's Hospital, Inc. |
Mast cell protease peptide inhibitors
|
US6852508B1
(en)
*
|
1997-02-28 |
2005-02-08 |
Genetics Institute, Llc |
Chemokine with amino-terminal modifications
|
ATE361102T1
(de)
*
|
1997-07-21 |
2007-05-15 |
Active Biotech Ab |
Zytolyse der geeigneten zielzellen mit superantigen konjugate mittels der induktion von t-zell aktivierung
|
US20030027257A1
(en)
*
|
1997-08-21 |
2003-02-06 |
University Technologies International, Inc. |
Sequences for improving the efficiency of secretion of non-secreted protein from mammalian and insect cells
|
US6037150A
(en)
*
|
1997-08-21 |
2000-03-14 |
University Technologies International Inc. |
Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
|
US20020127584A1
(en)
*
|
1997-09-18 |
2002-09-12 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030022298A1
(en)
*
|
1997-09-15 |
2003-01-30 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030032103A1
(en)
*
|
1997-09-18 |
2003-02-13 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DK1037927T3
(da)
|
1997-12-08 |
2004-09-06 |
Emd Lexigen Res Ct Corp |
Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
EP1071468B1
(de)
*
|
1998-04-15 |
2006-06-14 |
Lexigen Pharmaceuticals Corp. |
Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
|
AU751823B2
(en)
*
|
1998-05-14 |
2002-08-29 |
Merck Patent Gmbh |
Fused protein
|
BR9913331A
(pt)
*
|
1998-08-25 |
2001-05-15 |
Lexigen Pharm Corp |
Expressão e exportação de inibidores de angiogênese como imunofusinas
|
TR200504220T2
(tr)
*
|
1998-12-17 |
2007-04-24 |
Biogen Idec Ma Inc. |
Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
|
AU778939B2
(en)
*
|
1999-01-07 |
2004-12-23 |
Emd Lexigen Research Center Corp. |
Expression and export of anti-obesity proteins as Fc fusion proteins
|
AU3224700A
(en)
*
|
1999-02-08 |
2000-08-25 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
KR100312456B1
(ko)
|
1999-03-13 |
2001-11-03 |
윤덕용 |
슈도모나스 플루오레슨스 유래의 외래단백질 분비촉진유전자
|
EP1187852B1
(de)
*
|
1999-05-19 |
2007-08-08 |
EMD Lexigen Research Center Corp. |
Expression und export von interferon-alpha proteinen als fc fusionsproteine
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
WO2001008700A1
(en)
*
|
1999-07-28 |
2001-02-08 |
Genetics Institute, Inc. |
Preventing immune-mediated abortion by inhibiting costimulation
|
ATE316982T1
(de)
*
|
1999-08-09 |
2006-02-15 |
Lexigen Pharm Corp |
Mehrere zytokin-antikörper komplexen
|
EP1731531B1
(de)
|
1999-08-09 |
2012-05-30 |
Merck Patent GmbH |
Mehrere Zytokin-Antikörper Komplexe
|
EP1228214A2
(de)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietinformen mit verbesserten eigenschaften
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
DE60122286T2
(de)
*
|
2000-02-11 |
2007-08-02 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
US20030064950A1
(en)
*
|
2001-02-23 |
2003-04-03 |
Ntambi James M. |
Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
|
EP1261721A1
(de)
*
|
2000-03-08 |
2002-12-04 |
MERCK PATENT GmbH |
Menschlische ,extrazellulare, signlregulierte kinase
|
JP2003530120A
(ja)
*
|
2000-04-05 |
2003-10-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
新規な脂質結合タンパク質1
|
US20030176338A1
(en)
*
|
2000-05-05 |
2003-09-18 |
Klaus Ducker |
Novel serine-threonine kinase
|
AU2001262996A1
(en)
*
|
2000-05-08 |
2001-11-20 |
Georgetown University |
Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparum
|
JP2003532418A
(ja)
*
|
2000-05-12 |
2003-11-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
G−タンパク質シグナルの新規調整剤
|
BR0112111A
(pt)
*
|
2000-06-29 |
2003-05-06 |
Merck Patent Gmbh |
Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
EP1421190A2
(de)
*
|
2001-01-16 |
2004-05-26 |
Genset |
Metabolische gen-nukleinsäuren und polypeptide und ihre verwendungen
|
CA2440221C
(en)
*
|
2001-03-07 |
2013-02-05 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
EP1395279B1
(de)
|
2001-03-28 |
2011-10-05 |
Biogen Idec MA Inc. |
Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
DE60239454D1
(de)
*
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
GB0112818D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Lorantis Ltd |
Conjugate
|
US20050106659A1
(en)
*
|
2001-08-27 |
2005-05-19 |
Klemens Kaupmann |
Novel g-protein coupled receptor and dna sequences thereof
|
AU2002339862A1
(en)
*
|
2001-09-04 |
2003-05-26 |
Aventis Pharmaceuticals Inc. |
Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
|
US20030049694A1
(en)
*
|
2001-09-10 |
2003-03-13 |
Chung-Hsiun Wu |
Production of fusion proteins and use for identifying binding molecules
|
US6800462B2
(en)
*
|
2001-09-10 |
2004-10-05 |
Abgenomics Corporation |
Production of recombinant proteins in vivo and use for generating antibodies
|
EP1448588A4
(de)
|
2001-10-23 |
2006-10-25 |
Psma Dev Company L L C |
Psma-antikörper und proteinmultimere
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
WO2003048334A2
(en)
*
|
2001-12-04 |
2003-06-12 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
AU2002358110A1
(en)
*
|
2001-12-10 |
2003-07-09 |
Novartis Ag |
Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
US20050208044A1
(en)
*
|
2002-03-19 |
2005-09-22 |
Jane Barclay |
Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
|
AU2003234717A1
(en)
*
|
2002-04-12 |
2003-10-27 |
Bristol-Myers Squibb Company |
Novel polynucleotides encoding the human citron kinase polypeptide, bmsnkc 0020/0021
|
PT1512014E
(pt)
|
2002-06-13 |
2009-11-10 |
Merck Patent Gmbh |
Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante
|
US8025873B2
(en)
|
2002-06-20 |
2011-09-27 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US8029803B2
(en)
*
|
2002-06-20 |
2011-10-04 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US20040052777A1
(en)
*
|
2002-09-04 |
2004-03-18 |
Mark Nesbit |
Kringle polypeptides and methods for using them to inhibit angiogenesis
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
CA2510180C
(en)
*
|
2002-12-17 |
2012-09-11 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
|
PT1585546E
(pt)
|
2002-12-30 |
2008-11-14 |
Biogen Idec Inc |
Antagonistas de kim-1 e sua utilização para modular o sistema imunitário
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
AU2004257142A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
US8007805B2
(en)
|
2003-08-08 |
2011-08-30 |
Paladin Labs, Inc. |
Chimeric antigens for breaking host tolerance to foreign antigens
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
WO2005063820A2
(en)
*
|
2003-12-30 |
2005-07-14 |
Merck Patent Gmbh |
Il-7 fusion proteins
|
EP1699821B1
(de)
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
|
AU2005206277B2
(en)
|
2004-01-22 |
2011-06-23 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
AU2005227326B2
(en)
*
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
AU2005286662B2
(en)
|
2004-09-23 |
2011-10-06 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
KR20070085886A
(ko)
*
|
2004-12-09 |
2007-08-27 |
메르크 파텐트 게엠베하 |
감소된 면역원성의 il-7 변이체
|
TW200633718A
(en)
*
|
2004-12-16 |
2006-10-01 |
Applied Research Systems |
Treatment of hepatitis c in the asian population
|
CN100515491C
(zh)
*
|
2005-01-04 |
2009-07-22 |
健能隆医药技术(上海)有限公司 |
白介素-22的医药用途
|
EP1858925A2
(de)
*
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Antikörper und fc-fusionsproteine mit veränderter immunogenizität
|
CA2598454C
(en)
|
2005-02-18 |
2013-04-09 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
US7566456B2
(en)
*
|
2005-06-23 |
2009-07-28 |
Haiming Chen |
Allergen vaccine proteins for the treatment and prevention of allergic diseases
|
WO2007025991A2
(en)
*
|
2005-09-01 |
2007-03-08 |
Ares Trading S.A. |
Treatment of optic neuritis
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
EP1934341A1
(de)
*
|
2005-10-03 |
2008-06-25 |
AstraZeneca AB |
Fusionsproteine mit modulierter halbwertszeit in plasma
|
CA2624189A1
(en)
*
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP4860703B2
(ja)
*
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
JP2009521503A
(ja)
*
|
2005-12-22 |
2009-06-04 |
ディー・エイチ・ワイ・アンド・カンパニー・リミテッド |
インターロイキン−22結合タンパク質に対する抗体と、代謝性疾患の処置のためのその使用
|
JP5175214B2
(ja)
*
|
2005-12-30 |
2013-04-03 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
改良された安定性を有するインターロイキン−12p40変種
|
BRPI0620795A2
(pt)
|
2005-12-30 |
2011-11-22 |
Merck Patent Ges Mit Beschronkter Haftung |
anticorpos anti-cd19 imunogenicidade reduzida
|
US20070179094A1
(en)
|
2006-01-31 |
2007-08-02 |
Bayer Schering Pharma Ag |
Modulation of MDL-1 activity for treatment of inflammatory disease
|
US8940871B2
(en)
|
2006-03-20 |
2015-01-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
|
WO2007109733A2
(en)
|
2006-03-21 |
2007-09-27 |
The Johns Hopkins University |
Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
|
JP2009537605A
(ja)
|
2006-05-24 |
2009-10-29 |
メルク セローノ ソシエテ アノニム |
多発性硬化症を治療するためのクラドリビン・レジメン
|
AU2007271398B2
(en)
*
|
2006-07-06 |
2013-06-20 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
|
EP2069386A4
(de)
|
2006-07-21 |
2009-10-28 |
Life Technologies Corp |
Proteinmolekülgewichtsstandards mit hoher trennschärfe
|
ES2457072T3
(es)
|
2006-08-14 |
2014-04-24 |
Xencor, Inc. |
Anticuerpos optimizados que seleccionan como diana CD19
|
CA2660795C
(en)
*
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
EP2073833A2
(de)
*
|
2006-10-20 |
2009-07-01 |
Biogen Idec MA Inc. |
Behandlung von entmarkungserkrankungen mit löslichem lymphotoxin-beta-rezeptor
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
CN111518218A
(zh)
|
2006-11-02 |
2020-08-11 |
阿塞勒隆制药公司 |
Alk1受体和配体拮抗剂及其用途
|
PE20081250A1
(es)
*
|
2006-11-28 |
2008-10-07 |
Centelion |
FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
|
TW200907056A
(en)
*
|
2007-03-28 |
2009-02-16 |
Astrazeneca Ab |
New method
|
DK2160401T3
(da)
|
2007-05-11 |
2014-10-20 |
Altor Bioscience Corp |
Fusionsmolekyler og il-15-varianter
|
CN103641919B
(zh)
|
2007-05-30 |
2017-04-05 |
浦项工科大学校产学协力团 |
免疫球蛋白融合蛋白
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
EP4098661A1
(de)
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Fc-varianten mit veränderter bindung an fcrn
|
CN105963695A
(zh)
|
2008-05-02 |
2016-09-28 |
阿塞勒隆制药公司 |
用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
|
PT2352763E
(pt)
*
|
2008-10-01 |
2016-06-02 |
Amgen Res (Munich) Gmbh |
Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular
|
KR101026526B1
(ko)
*
|
2009-01-23 |
2011-04-01 |
한국과학기술연구원 |
대장균에서 외래단백질을 분비 생산하는 방법
|
EP3495000A1
(de)
|
2009-02-17 |
2019-06-12 |
Cornell Research Foundation, Inc. |
Verfahren und kits zur diagnose von krebs und vorhersage des therapeutischen werts
|
CN102405230A
(zh)
*
|
2009-04-22 |
2012-04-04 |
默克专利有限公司 |
具有修饰的FcRn结合位点的抗体融合蛋白
|
JP6166041B2
(ja)
|
2009-06-15 |
2017-07-19 |
バレリオン セラピューティクス, エルエルシー |
ミオチューブラリン1(mtm1)ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
KR101061017B1
(ko)
*
|
2009-10-23 |
2011-08-31 |
(주) 수파드엘릭사 |
암세포의 성장 및/또는 전이 억제용 약학 조성물
|
CA2782333C
(en)
|
2009-12-02 |
2019-06-04 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
US8637637B2
(en)
|
2010-01-12 |
2014-01-28 |
Bill Nai-Chau Sun |
Fc fusion proteins of human growth hormone
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
CN102947341B
(zh)
|
2010-01-19 |
2018-07-06 |
哈佛大学校长及研究员协会 |
用于病原体检测和治疗的工程化调理素
|
AU2011218294A1
(en)
|
2010-02-16 |
2012-08-30 |
Medimmune, Llc |
HSA-related compositions and methods of use
|
EP2563385B1
(de)
*
|
2010-04-28 |
2017-08-02 |
Oncoimmune Inc. |
Verfahren zur verwendung von löslichem cd24 zur behandlung rheumatoider arthritis
|
US20130231464A1
(en)
|
2010-04-28 |
2013-09-05 |
Oncolmmune, Inc. |
Methods of use of soluble cd24 for therapy of rheumatoid arthritis
|
EP3029066B1
(de)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antikörper mit modifizierten isoelektrischen punkten
|
EP2918607B1
(de)
|
2010-09-21 |
2017-11-08 |
Altor BioScience Corporation |
Multimere il-15-lösliche fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
EP2680874A2
(de)
|
2011-03-04 |
2014-01-08 |
Pfizer Inc |
Edn3-ähnliche peptide und ihre verwendung
|
EP2505640A1
(de)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
|
CN108341863A
(zh)
|
2011-04-20 |
2018-07-31 |
阿塞勒隆制药公司 |
内皮糖蛋白多肽及其用途
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN105189542A
(zh)
|
2013-02-20 |
2015-12-23 |
瓦莱里昂治疗有限责任公司 |
用于治疗庞贝氏症的方法和组合物
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
LT2981822T
(lt)
|
2013-05-06 |
2020-12-28 |
Scholar Rock, Inc. |
Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
|
US20150056199A1
(en)
|
2013-08-22 |
2015-02-26 |
Acceleron Pharma, Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
KR102354787B1
(ko)
|
2013-10-25 |
2022-01-24 |
악셀레론 파마 인코포레이티드 |
섬유화 질환을 치료하기 위한 엔도글린 펩티드
|
WO2015085311A1
(en)
|
2013-12-07 |
2015-06-11 |
Case Western Reserve University |
Compositions and methods of treating thrombosis
|
EP3094646B1
(de)
|
2014-01-13 |
2020-04-15 |
Valerion Therapeutics, LLC |
Internalisierung von gruppen
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015237184B2
(en)
|
2014-03-28 |
2020-11-26 |
Xencor, Inc. |
Bispecific antibodies that bind to CD38 and CD3
|
AU2015269333B2
(en)
|
2014-06-04 |
2020-05-07 |
Acceleron Pharma, Inc. |
Methods and compositions for treatment of disorders with follistatin polypeptides
|
ES2899890T3
(es)
|
2014-06-30 |
2022-03-15 |
Altor Bioscience Corp |
Moléculas basadas en IL-15 y métodos de uso de las mismas
|
EP3677285B1
(de)
|
2014-08-04 |
2023-12-13 |
Case Western Reserve University |
Gezielte peptide zur erkennung von prostatakrebs
|
US10603359B2
(en)
|
2014-10-30 |
2020-03-31 |
Acceleron Pharma Inc. |
Methods and compositions using GDF15 polypeptides for increasing red blood cells
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
CU24597B1
(es)
|
2014-11-26 |
2022-05-11 |
Xencor Inc |
Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
ES2901273T3
(es)
|
2015-04-06 |
2022-03-21 |
Subdomain Llc |
Polipéptidos que contienen dominios de unión de novo y usos de los mismos
|
CN107849117B
(zh)
|
2015-06-05 |
2022-08-26 |
艾比欧公司 |
用于治疗纤维化的内皮抑素片段和变体
|
EP4218792A1
(de)
|
2015-08-04 |
2023-08-02 |
Acceleron Pharma Inc. |
Zusammensetzung zur behandlung von myeloproliferativen erkrankungen
|
EP4137158A1
(de)
|
2015-08-07 |
2023-02-22 |
Imaginab, Inc. |
Gegen moleküle gerichtete antigenbindende konstrukte
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
KR102463844B1
(ko)
|
2016-05-27 |
2022-11-08 |
알토 바이오사이언스 코포레이션 |
Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP7142630B2
(ja)
|
2016-10-14 |
2022-09-27 |
ゼンコア インコーポレイテッド |
IL15/IL15Rαヘテロ二量体FC-融合タンパク質
|
KR102392142B1
(ko)
|
2016-10-21 |
2022-04-28 |
알토 바이오사이언스 코포레이션 |
다량체 il-15 기반 분자
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
CA3216726A1
(en)
|
2017-03-06 |
2018-09-13 |
Altor Bioscience Corporation |
Il-15-based fusions to il-12 and il-18
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
WO2018204594A1
(en)
|
2017-05-04 |
2018-11-08 |
Acceleron Pharma Inc. |
Tgf-beta receptor type ii fusion proteins and uses thereof
|
EP3630158B1
(de)
*
|
2017-05-22 |
2022-07-13 |
Oncoimmune, Inc. |
Verfahren zur verwendung von löslichem cd24 zur behandlung von immunbedingten unerwünschten ereignissen in krebstherapien
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
WO2019046313A1
(en)
|
2017-08-28 |
2019-03-07 |
Altor Bioscience Llc |
IL-15 BASED FUSIONS WITH IL-7 AND IL-21
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2018369639A1
(en)
|
2017-11-14 |
2020-04-23 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
MX2020004935A
(es)
|
2017-11-14 |
2020-09-25 |
Arcellx Inc |
Terapias con celulas inmunitarias multifuncionales.
|
KR20230019227A
(ko)
*
|
2017-11-17 |
2023-02-07 |
그리폴스 다이어그노스틱 솔루션즈 인크. |
신규한 포유동물 발현 인간 면역결핍 바이러스 외피 단백질 항원
|
WO2019125732A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
US11168138B2
(en)
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
EP3773911A2
(de)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimere antikörper, die das fibroblastenaktivierungsprotein binden
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
CN110964116A
(zh)
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc融合蛋白及其缀合物
|
CN113195523A
(zh)
|
2018-10-03 |
2021-07-30 |
Xencor股份有限公司 |
IL-12异源二聚体Fc融合蛋白
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
WO2022065643A1
(ko)
*
|
2020-09-28 |
2022-03-31 |
한국화학연구원 |
분비 신호서열에 융합된 표적산물 결합 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물, 그를 포함하는 조성물 및 그를 이용하여 표적산물을 생산하는 방법
|
KR102625766B1
(ko)
*
|
2020-09-28 |
2024-01-17 |
한국화학연구원 |
분비 신호서열에 융합된 표적산물 결합 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물, 그를 포함하는 조성물 및 그를 이용하여 표적산물을 생산하는 방법
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|